|   From the Trenches

Leave No Stone Unturned: A Pipeline Story

Building a leading gene therapy pipeline in under two years (and a lot of air miles): how to persevere and make the calls that matter.

Throughout a career in business development I’ve sat at every seat at the negotiating table, but I count my experience building AVROBIO’s leading lentiviral vector (LV) ex vivo gene therapy pipeline as perhaps my most satisfying and extraordinary time in biotech.

This blog was written by Deanna Petersen, CBO of AVROBIO (@dmp9818), as part of the From The Trenches feature of LifeSciVC.

Read more.